Journal article · 2017 · Open access
Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies
Malaria Journal, 16(1), 143 · Published 7 April 2017 · DOI 10.1186/s12936-017-1775-2
In brief
“Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies” is a 2017 journal article by Moe Kyaw Myint and 5 co-authors, published in Malaria Journal. OpenAlex counts 29 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Malaria Journal.
- Citations
- 29
- Most cited in
- 2019 (10)
- Field-weighted impact
- 3.73
- References
- 10
- Authors
- 6
Abstract
BACKGROUND: In Myanmar, three types of artemisinin-based combination therapy (ACT) are recommended as first-line treatment of uncomplicated falciparum malaria: artemether-lumefantrine (AL), artesunate-mefloquine (AS + MQ), and dihydroartemisinin-piperaquine (DP). Resistance to both artemisinins and ACT partner drugs has been reported from the Greater Mekong Sub-region, and regular efficacy monitoring of the recommended ACT is conducted in Myanmar. This paper reports on results from studies to monitor the efficacy of the three forms of ACT in sentinel sites in northern Myanmar, and investigations of mutations in the Kelch13 (k13) propeller domain. METHODS: Seven therapeutic efficacy studies were conducted in 2011-12 and 2014 in three sentinel sites in Myanmar (Tamu, Muse, Tabeikkyin). Three studies were done for the evaluation of AL (204 patients), two studies for AS + MQ (119 patients) and two studies for DP (147 patients). These studies were done according to 2009 standard WHO protocol. Polymorphisms in the k13 propeller domain were examined in dried blood spots collected on day 0. The primary endpoint was adequate clinical and parasitological response (ACPR) on day 28 for AL and on day 42 for DP and AS + MQ, corrected to exclude re-infection using polymerase chain reaction (PCR) genotyping. Safety data were collected through self-reporting. RESULTS: PCR-corrected ACPR was 97.2-100% for AL, 98.6-100% for AS + MQ and 100% for DP across the study sites and years. All studies found a prevalence of k13 mutations (>440) above 23% in the day-0 samples. The F446I mutation was the most common mutation, making up 66.0% of the mutations found. Seven out of nine day-3 positive patients were infected with k13 wild type parasites. The remaining two cases with day-3 parasitaemia had the P574L mutation. CONCLUSIONS: The efficacy of AL, AS + MQ and DP remains high in northern Myanmar despite widespread evidence of k13 mutations associated with delayed parasite clearance. This study showed that already in 2012 there was a high frequency of k13 mutations in Myanmar on the border with India. The high efficacy of the recommended ACT gives confidence in the continued recommendation of the use of these treatments in Myanmar. Trial registration numbers ACTRN12611001245987 (registered 06-12-2011) and ACTRN12614000216617 (registered 28-02-2014).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Myint, M. K., Rasmussen, C., Thi, A., Bustos, D., Ringwald, P., & Lin, K. (2017). Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies. Malaria Journal, 16(1), 143. https://doi.org/10.1186/s12936-017-1775-2
MLA 9
Myint, Moe Kyaw, et al. “Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies.” Malaria Journal, vol. 16, no. 1, 2017, p. 143. https://doi.org/10.1186/s12936-017-1775-2.
Chicago
Myint, Moe Kyaw, Charlotte Rasmussen, Aung Thi, Dorina Bustos, Pascal Ringwald, and Khin Lin. 2017. “Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies.” Malaria Journal 16 (1): 143. https://doi.org/10.1186/s12936-017-1775-2.
Harvard
Myint, M. K. et al. (2017) ‘Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies’, Malaria Journal, 16(1), p. 143. doi:10.1186/s12936-017-1775-2.
IEEE
M. K. Myint, C. Rasmussen, A. Thi, D. Bustos, P. Ringwald, and K. Lin, “Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies,” Malaria Journal, vol. 16, no. 1, p. 143, 2017, doi: 10.1186/s12936-017-1775-2.
BibTeX
@article{myint2017therapeutic,
title = {{Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies}},
author = {Myint, Moe Kyaw and Rasmussen, Charlotte and Thi, Aung and Bustos, Dorina and Ringwald, Pascal and Lin, Khin},
journal = {Malaria Journal},
year = {2017},
volume = {16},
number = {1},
pages = {143},
doi = {10.1186/s12936-017-1775-2},
url = {https://doi.org/10.1186/s12936-017-1775-2}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2018 | 4 | |
| 2019 | 10 | |
| 2020 | 3 | |
| 2021 | 4 | |
| 2022 | 2 | |
| 2023 | 1 | |
| 2024 | 3 | |
| 2026 | 2 |
Its field-weighted citation impact is 3.73: it has been cited 3.73 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- artemisinin resistance
- falciparum malaria
- artemisinin-based combination therapy
- treatment efficacy
- artemether-lumefantrine
- artesunate-mefloquine
- dihydroartemisinin-piperaquine
- parasite clearance time
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Myint, M. K., Rasmussen, C., Thi, A., Bustos, D., Ringwald, P., & Lin, K. (2017). Therapeutic efficacy and artemisinin resistance in northern Myanmar: evidence from in vivo and molecular marker studies. Malaria Journal, 16(1), 143. https://doi.org/10.1186/s12936-017-1775-2
How many times has this paper been cited?
29 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Malaria Journal: sign in and open the PDF from this page.
Who wrote this paper?
Moe Kyaw Myint, Charlotte Rasmussen, Aung Thi, Dorina Bustos, Pascal Ringwald, Khin Lin.
What is the DOI of this paper?
10.1186/s12936-017-1775-2, permanently at https://doi.org/10.1186/s12936-017-1775-2. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.